Welcome
Support Centre
17 May 2012 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ ...Back to search results ] [ Print-friendly version ]
Conventional Versus Automated Measurement of Blood Pressure in the Office
ISRCTN ISRCTN12912185
ClinicalTrials.gov identifier
Public title Conventional Versus Automated Measurement of Blood Pressure in the Office
Scientific title
Acronym The CAMBO Study
Serial number at source 392-2005
Study hypothesis Automated office systolic blood pressure (SBP) recordings in routine clinical practice using the BpTRU device will reflect more accurately the mean awake ambulatory systolic blood pressure (BP) than manual BP readings taken with conventional mercury sphygmomanometry. This should lead to improvements in the management of systolic hypertension with optimization of drug therapy in practices using the BpTRU device.
Lay summary
Ethics approval Approved by the Sunnybrook Research Ethics Board (REB) on 20/10/2005, reference number: 392-2005
Study design A cluster randomized, controlled, clinical trial
Countries of recruitment Canada
Disease/condition/study domain Systolic hypertension
Participants - inclusion criteria Both treated and untreated patients with systolic hypertension under routine family physician (FP) care. For untreated patients, routine office SBP as measured by the patient's FP at the last routine office visit using a mercury device must have SBP ≥160 mmHg and diastolic blood pressure (DBP) ≤95 mmHg. For patients already receiving antihypertensive therapy, the last routine office BP as measured by the patient's FP using mercury sphygmomanometry must be SBP ≥140 mmHg and DBP ≤90 mmHg.
Participants - exclusion criteria 1. Presence of target organ damage such as myocardial infarction (MI), stroke, and serum creatinine twice the upper limit of normal
2.Diabetes mellitus treated with insulin or oral hypoglycemic therapy
3. Secondary hypertension
4. Participation in another research study involving measurement of BP
5. Patient's insistence on using self BP measurement outside of the study
6. Any conditions or circumstances which might preclude the successful completion of the study
Anticipated start date 15/01/2006
Anticipated end date 15/01/2008
Status of trial Completed
Patient information material
Target number of participants 500
Interventions Measurement of blood pressure using automated office BP with a target of 135 mmHg versus office mercury sphygmomanometer with a target of 140 mmHg
Primary outcome measure(s) Differences in SBP between the mean awake ambulatory BP and the manual office BP versus the difference in SBP between the mean awake ambulatory BP and the automated office BP
Secondary outcome measure(s) 1. Differences in SBP between the mean awake 24-hour ambulatory BP and the manual office BP versus the automated BP
2. Differences in SBP between the mean nocturnal ambulatory BP and the manual office BP versus the automated BP
3. Differences in coefficients of correlation (r value) between the awake ambulatory BP and the manual versus automated office BP
4. Differences in the coefficients of correlation between the manual office SBP versus the automated BP versus the mean awake, 24-hour or nocturnal ambulatory SBP
5. Differences in the primary outcome between men and women
6. Adverse effects related to management of hypertension with manual versus automated BP
7. Differences in intensity of drug therapy for manual versus automated office BP patients
8. Frequency of medication changes for manual versus automated office BP patients
9. Cost of drug therapy at year two for manual versus automated office BP patients
10. Clinical events of serious adverse events reported for manual versus automated office BP patients
Sources of funding Heart and Stroke Foundation of Ontario
Trial website
Publications
Contact name Dr  Martin  Myers
  Address 2075 Bayview Avenue
  City/town Toronto
  Zip/Postcode M4N 3M5
  Country Canada
  Email martin.myers@sunnybrook.ca
Sponsor Heart and Stroke Foundation of Ontario (Canada)
  Address 1920 Yonge Street
Fourth Floor
  City/town Toronto
  Zip/Postcode M4S 3E2
  Country Canada
  Email efreeman@hsf.on.ca
Date applied 11/05/2006
Last edited 19/06/2006
Date ISRCTN assigned 19/06/2006
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 ISRCTN unless otherwise stated.


BioMed Central